রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন।
DELPARK 2MG Tablet is indicated for:
Symptomatic treatment of Parkinson’s disease as monotherapy or in combination with levodopa.
Management of moderate to severe Restless Legs Syndrome (RLS).
Pramipexole is a dopamine D2/D3 receptor agonist that mimics dopamine's effects by stimulating the receptors directly. It alleviates motor and non-motor symptoms of Parkinson’s disease and reduces sensory and motor disturbances in RLS.
Parkinson’s Disease:
Starting dose: 0.125 mg three times daily.
Gradually increase every 5-7 days to a maximum of 4.5 mg/day in divided doses.
Maintenance dose varies based on clinical response.
Restless Legs Syndrome (RLS):
Start with 0.125 mg once daily, taken 2-3 hours before bedtime.
Dose adjustments depend on symptom severity, not exceeding 0.5 mg/day.
Administration: Take orally, with or without food, as directed by a physician.
Drug Interactions:
Enhanced sedation with CNS depressants or alcohol.
May interact with dopamine antagonists like antipsychotics, reducing efficacy.
Food Interactions: Taking with food can minimize gastrointestinal side effects.
Known hypersensitivity to Pramipexole or any inactive ingredient in the formulation.
Common side effects:
Nausea, dizziness.
Sleep disturbances, fatigue.
Rare or severe side effects:
Hallucinations, compulsive behaviors.
Hypotension, somnolence.
Pregnancy: Pramipexole falls under Category C; use only if benefits outweigh potential risks.
Lactation: Not recommended as it may inhibit prolactin secretion, affecting milk production.
Monitor for sudden onset of sleep or drowsiness during daily activities.
Caution in patients with a history of psychiatric or impulse control disorders.
Gradual dose reduction is necessary to avoid withdrawal symptoms when discontinuing.
Dopamine agonist for Parkinson’s disease and RLS.
Store in a cool, dry place below 25°C.
Protect from light and moisture.
Keep out of reach of children.